Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose

被引:24
作者
Birmingham, MC
Guarino, R
Heller, A
Wilton, JH
Shah, A
Hejmanowski, L
Nix, DE
Schentag, JJ
机构
[1] Millard Fillmore Hlth Syst, Clin Pharmacokinet Lab, Buffalo, NY 14209 USA
[2] Bayer Corp, Div Pharmaceut, W Haven, CT USA
关键词
D O I
10.1093/jac/43.suppl_1.43
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Intravenous ciprofloxacin is frequently prescribed for the treatment of infections due to nosocomially acquired Gram-negative organisms, including those originating in the respiratory tract. In this study, the concentrations of ciprofloxacin In serum and lung tissue were determined by HPLC in patients undergoing lung surgery. A total of 22 patients scheduled for lung surgery received a single 400 mg iv dose of ciprofloxacin administered as a 1 h infusion. A specimen of healthy lung tissue was obtained from resected lung from 18 of the patients for analysis of ciprofloxacin concentration during the following time intervals after infusion tone sample/patient): 0-2, 2-4, 4-8 and 8-12 h. Corresponding mean serum and tissue concentrations were 2.37 mg/L and 3.84 mg/kg (0-2 h), 1.18 mg/L and 1.92 mg/kg (2-4 h), 0.69 mg/L and 1.77 mg/kg (4-8 h), and 0.13 mg/L and 0.67 mg/kg (8-12 h). Ciprofloxacin distributed rapidly to lung tissue, as seen by the high concentrations in the lung tissue as early as 2 h after infusion. Concentrations in lung tissue were generally higher than those in serum (tissue:serum ratios ranged from 1.7 to 7.1). The mean tissue concentrations found in this study remained above the MIC for most susceptible organisms.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 20 条
  • [1] BACRACHEVA N, 1991, INT J CLIN PHARM TH, V29, P352
  • [2] PULMONARY DISPOSITION OF ANTIMICROBIAL AGENTS - METHODOLOGICAL CONSIDERATIONS
    BALDWIN, DR
    HONEYBOURNE, D
    WISE, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (06) : 1171 - 1175
  • [3] COMPARATIVE BRONCHOALVEOLAR CONCENTRATIONS OF CIPROFLOXACIN AND LOMEFLOXACIN FOLLOWING ORAL-ADMINISTRATION
    BALDWIN, DR
    WISE, R
    ANDREWS, JM
    GILL, M
    HONEYBOURNE, D
    [J]. RESPIRATORY MEDICINE, 1993, 87 (08) : 595 - 601
  • [4] BERGER BG, 1986, CURRENT SELECTED RES, V1, P97
  • [5] CARUSO E, 1988, 6 MED C CHEM TAOR IT
  • [6] AZITHROMYCIN (CP-62,993) IN ACUTE EXACERBATIONS OF CHRONIC-BRONCHITIS - AN OPEN CLINICAL, MICROBIOLOGICAL AND PHARMACOKINETIC STUDY
    DAVIES, BI
    MAESEN, FPV
    GUBBELMANS, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 23 (05) : 743 - 751
  • [7] Ciprofloxacin - An updated review of its pharmacology, therapeutic efficacy and tolerability
    Davis, R
    Markham, A
    Balfour, JA
    [J]. DRUGS, 1996, 51 (06) : 1019 - 1074
  • [8] TREATMENT OF SEVERE PNEUMONIA IN HOSPITALIZED-PATIENTS - RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING INTRAVENOUS CIPROFLOXACIN WITH IMIPENEM-CILASTATIN
    FINK, MP
    SNYDMAN, DR
    NIEDERMAN, MS
    LEEPER, KV
    JOHNSON, RH
    HEARD, SO
    WUNDERINK, RG
    CALDWELL, JW
    SCHENTAG, JJ
    SIAMI, GA
    ZAMECK, RL
    HAVERSTOCK, DC
    REINHART, HH
    ECHOLS, RM
    HELSMOORTEL, C
    SOJASTRZEPA, D
    SCHWAITZBERG, S
    BAREFOOT, L
    FEIN, AM
    FEINSILVER, SH
    ILOWITE, JS
    CLARE, N
    SCHULMAN, D
    JONES, CB
    GRIFFIN, RI
    WROBEL, CW
    BALLOW, CH
    AMSDEN, G
    MITCHELL, P
    BESS, T
    WILKINS, W
    BROWN, RB
    MCGEE, W
    SAFFORD, MJ
    LEVINE, DP
    LERNER, SA
    KRUSE, JA
    BANDER, JJ
    MCNEIL, P
    MUNKARAH, M
    SUMMER, WR
    DEBOISBLANC, B
    LEVISON, ME
    KORZENIOWSKI, O
    SIGLER, A
    BALDASSARRE, J
    WALSH, P
    SAMEL, C
    SESSLER, CN
    POLK, RE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (03) : 547 - 557
  • [9] PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS
    FORREST, A
    NIX, DE
    BALLOW, CH
    GOSS, TF
    BIRMINGHAM, MC
    SCHENTAG, JJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) : 1073 - 1081
  • [10] FORST H, 1989, ARZNEIMITTEL-FORSCH, V39-1, P618